Effects of PI3K inhibitor NVP-BKM120 on acquired resistance to gefitinib of human lung adenocarcinoma H1975 cells

Abstract

The effects of class I PI3K inhibitor NVP-BKM120 on cell proliferation, cell cycle distribution, cellular apoptosis, phosphorylation of several proteins of the PI3K/AKT signaling pathway and the mRNA expression levels of HIF1-α, VEGF and MMP9 in the acquired gefitinib resistant cell line H1975 were investigated, and whether NVP-BKM120 can overcome the acquired resistance caused by the EGFR T790M mutation and the underlying mechanism were explored. MTT assay was performed to detect the effect of gefitinib, NVP-BKM120, NVP-BKM120 plus 1 μmol/L gefitinib on growth of H1975 cells. The distribution of cell cycle and apoptosis rate of H1975 cells were examined by using flow cytometry. The mRNA expression levels of tumor-related genes such as HIF1-α, VEGF and MMP9 were detected by using real-time quantitative PCR. Western blotting was used to detect the expression level of phosphorylated proteins in the PI3K/AKT signaling pathway, such as Ser473-p-AKT, Ser235/236-p-S6 and Thr70-p-4E-BP1, as well as total AKT, S6 and 4E-BP1. The results showed that the NVP-BKM120 could inhibit the growth of H1975 cells in a concentration-dependent manner, and H1975 cells were more sensitive to NVP-BKM120 than gefitinib (IC₅₀:1.385 vs. 15.09 μmol/L respectively), whereas combination of NVP-BKM120 and gefitinib (1 μmol/L) did not show more obvious effect than NVP-BKM120 used alone on inhibition of cell growth (P>0.05). NVP-BKM120 (1 μmol/L) increased the proportion of H1975 cells in G₀-G₁ phase and the effect was concentration-dependent, and 2 μmol/L NVP-BKM120 promoted apoptosis of H1975 cells. There was no significant difference in the proportion of H1975 cells in G₀-G₁ phase and apoptosis rate between NVP-BKM120-treated alone group and NVP-BKM120 plus genfitinib (1 μmol/L)-treated group or between DMSO-treated control group and gefitinib (1 μmol/L)-treated alone group (P>0.05 for all). It was also found that the mRNA expression levels of these genes were down-regulated by NVP-BKM120 (1 μmol/L), and NVP-BKM120 (1 μmol/L) or NVP-BKM120 (1 μmol/L) plus gefitinib (1 μmol/L) obviously inhibited the activation of Akt, S6 and 4E-BP1 as compared with control group, but single use of gefitinib (1 μmol/L) exerted no significant effect. These data suggested that NVP-BKM120 can overcome gefitinib resistance in H1975 cells, and the combination of NVP-BKM120 and gefitinib did not have additive or synergistic effects. It was also concluded that NVP-BKM120 could overcome the acquired resistance to gefitinib by down-regulating the phosphorylated protein in PI3K/AKT signal pathways in H1975 cells, but it could not enhance the sensitivity of H1975 cells to gefitinib.

Keywords

lung adenocarcinoma H1975 cell line / NVP-BKM120 / acquired gefitinib resistance

References

[1] JemalA, SiegelR, XuJ, et al.. Cancer statistics, 2010. CA Cancer J Clin, 2010, 60(5): 277-300

[2] JeremicB, MilicicB, DagovicA, et al.. Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy. J Cancer Res Clin Oncol, 2003, 129(2): 114-122

[3] WakeleeHA, BernardoP, JohnsonDH, et al.. Changes in the natural history of nonsmall cell lung cancer (NSCLC)-comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. Cancer, 2006, 106(10): 2208-2217

[4] MolinaJR, YangP, CassiviSD, et al.. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc, 2008, 83(5): 584-594

[5] PfisterDG, JohnsonDH, AzzoliCG, et al.. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: updated 2003. J Clin Oncol, 2004, 22(2): 330-353

[6] ShepherdFA, DanceyJ, RamlauR, et al.. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 2000, 18(10): 2095-2103

[7] IdbaihA, AimardJ, BoisselierB, et al.. Epidermal growth factor receptor mutations in lung cancer. J Neuropathol Appl Neurobiol, 2009, 35(2): 208-213

[8] EttingerDS. Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer. Oncologist, 2006, 11(4): 358-373

[9] SharmaSV, BellDW, SettlemanJ, et al.. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer, 2007, 7(3): 169-181

[10] PaezJG, JännePA, LeeJC, et al.. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 304(5676): 1497-1500

[11] CostaDB, KobayashiS, TenenDG, et al.. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer, 2007, 58(1): 95-103

[12] KobayashiS, BoggonTJ, DayaramT, et al.. EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N Engl J Med, 2005, 352(8): 786-792

[13] PaoW, MillerVA, PolitiKA, et al.. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med, 2005, 2(3): e73

[14] YunCH, MengwasserKE, TomsAV, et al.. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA, 2008, 105(6): 2070-2075

[15] EngelmanJA, ZejnullahuK, MitsudomiT, et al.. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 2007, 316(5827): 1039-1043

[16] BeanJ, BrennanC, ShihJY, et al.. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA, 2007, 104(52): 20932-20937

[17] BuonamiciS, WilliamsJ, MorrisseyM, et al.. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med, 2010, 2(51): 51-70

[18] AzizSA, JilaveanuLB, ZitoC, et al.. Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin Cancer Res, 2010, 16(24): 6029-6039

[19] GendreauSB, VenturaR, KeastP, et al.. Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. Clin Cancer Res, 2007, 13(12): 3713-3723

[20] TangZ, DuR, JiangS, et al.. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer, 2008, 99(6): 911-922

[21] RhoJK, ChoiYJ, RyooBY, et al.. P53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer. Cancer Res, 2007, 67(3): 1163-1169

[22] SchmittgenTD, LivakKJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc, 2008, 3(6): 1101-1108

[23] WangL, ZhangQ, ZhangJ, et al.. PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer, 2011, 11: 248

[24] NicholsonKM, AndersonNG. The protein kinase B/Akt signaling pathway in human malignancy. Cell Signal, 2002, 14(5): 381-395

[25] EngelmanJA, LuoJ, CantleyLC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet, 2006, 7(8): 606-619

[26] AzizSA, DaviesM, PickE, et al.. Phosphatidylinositol-3-kinase as a therapeutic target in melanoma. Clin Cancer Res, 2009, 15(9): 3029-3036

[27] MartinKA, BlenisJ. Coordinate regulation of translation by the PI 3-kinase and mTOR pathways. Adv Cancer Res, 2002, 86: 1-39

[28] RichardsonCJ, SchalmSS, BlenisJ. PI3-kinase and TOR: PIKTORing cell growth. Semin Cell Dev Biol, 2004, 15(2): 147-159

[29] KuboT, YamamotoH, LockwoodWW, et al.. MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer, 2009, 124(8): 1778-1784

[30] TestaJR, BellacosaA. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA, 2001, 98(20): 10 983-10 985

[31] HanadaM, FengJ, HemmingsBA. Structure, regulation and function of PKB/AKT-a major therapeutic target. Biochim Biophys Acta, 2004, 1697(1-2): 3-16

[32] GaoN, NesterRA, SarkarMA. 4-Hydroxy estradiol but not 2-hydroxy estradiol induces expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor A through phosphatidylinositol 3-kinase/ Akt/FRAP pathway in OVCAR-3 and A27802CP70 human ovarian carcinoma cells. Toxicol Appl Pharmacol, 2004, 196(1): 124-135

[33] LaughnerE, TaghaviP, ChilesK, et al.. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol, 2001, 21(12): 3995-4004